Reducing Benzodiazepines: Tapering, Treatment, and Recovery

Treatment is more than taking fewer pills. It must address withdrawal risk, the original reason for treatment, and any substance use disorder.

This is Part 2 of a two-part series. Part 1 explains how dependence develops, why it is not addiction, and the first safe step.

Read this first: Abruptly stopping a benzodiazepine can cause dangerous withdrawal, including seizures and delirium. Do not stop, switch, or change a benzodiazepine dose without a qualified clinician. Call 911 for a seizure, severe confusion, hallucinations, inability to wake, slow or stopped breathing, or immediate danger.

A safe taper is not a test of willpower. It is a medical plan that gives the nervous system time to adjust. The plan also has to protect sleep, mental health, daily function, and safety. For some people, it must address a benzodiazepine use disorder or other substance use at the same time.12

The goal is not to endure the most distress in the shortest time. It is to find the safest next step, watch the response, and change the plan when the facts change.

Zoom

There is no single benzodiazepine treatment plan

Four situations may look alike at first. One person may have physical dependence after taking a prescription as directed. Another may have a benzodiazepine use disorder, which means a harmful pattern such as lost control or use despite serious harm. A third person may be mixing the drug with alcohol, opioids, or an unknown pill. A fourth may already be in severe withdrawal. With regular use, the nervous system can adapt, and a fast drop can cause withdrawal. That physical dependence is not, by itself, addiction (Part 1 explains the difference). These problems can overlap, but they still need different care.12

Care may use one lane or several. Physical dependence alone does not prove a need for addiction care or a residential program. If a use disorder is present, withdrawal care is only one part of treatment. The first anxiety, sleep, seizure, or other problem may also still need care.

Which treatment lane fits the situation?

The assessment comes before the taper

A good assessment starts with what the person took. The care team needs the drug name, route, formulation, source, dose pattern, and length of use. It also needs to know what happened after a missed dose or past cut. Bring bottles or label photos if they are handy. If a pill came from an unknown source, say that its contents and strength are unknown. A color, stamp, or seller’s claim cannot settle that question.121

Past events matter. Report any seizure, delirium, hallucinations, overdose, fall, crash, or emergency visit. List alcohol, opioids, Z-drugs, gabapentin, pregabalin, cannabis, stimulants, sleep aids, and other sedatives. The review should cover breathing, liver and kidney health, pregnancy, sleep, pain, memory, trauma, and suicide risk. It should also check for mania or psychosis. Finally, it should name the problem the drug was meant to treat.1

Daily life can change the safest plan. Housing may be unstable. A relationship may be unsafe. Food, rides, storage, or follow-up may be hard to get. These facts may call for case work or more support. They do not diagnose a use disorder.

A screen can start a talk. It cannot make the diagnosis alone. A routine urine test may miss lorazepam, clonazepam, some alprazolam use, or newer drugs. A more exact test still finds only what its panel can detect. No screening or toxicology result can by itself predict a withdrawal seizure or choose the right level of care. A negative result does not prove that no drug was taken. It also does not prove that a pill was real or that a sudden stop is safe.122

Some people need more experts before a plan is made. This includes people who are pregnant, postpartum, or nursing. It also includes teens, people with past severe withdrawal, and people with epilepsy. Serious liver, kidney, lung, or sleep-breathing disease matters too. So does unstable bipolar or psychotic illness. U.S. data show that teens receive these medicines, but adult taper trials do not establish what works for them. A teen’s plan needs pediatric or adolescent specialty review plus clear caregiver, consent, and assent planning under the rules that apply. The team may also need help from obstetric, brain, sleep, addiction, or pharmacy specialists.1293042

Where treatment should happen

Most tapers can happen in outpatient care. A prescriber, pharmacist, therapist, and addiction clinician may work as a team. More visits do not always mean more limits. The best setting is the least strict one that can manage risk and keep follow-up steady. No benzodiazepine-specific comparative study shows that intensive outpatient care, partial hospitalization, or residential rehabilitation gives better discontinuation or sustained-recovery outcomes than another setting. These services may provide structure or treat a separate psychiatric or substance-use need. Teams choose them by function and risk, not proven superiority.1933

A hospital may be needed when grave harm cannot be managed outside it. It may also be needed when an unstable illness makes outpatient care unsafe. Severe withdrawal, or a high chance of it, is another reason. Past seizure or delirium raises concern. So can a very high or unknown dose, overdose risk, current suicide danger, or use of many drugs. A care team must weigh these facts. This table cannot place a reader.1

Older adults need a two-sided review. Falls, confusion, slow drug clearance, and drug buildup can raise risk at home. Yet a hospital stay can worsen delirium in a frail person. The team must compare both risks.130

Outpatient, residential, or inpatient?

This table explains functions. It cannot place or diagnose a reader.

The foundation: a slow, flexible, shared taper

The 2025 Joint Clinical Practice Guideline calls for shared choices and gradual change. The team should check the person after each cut. It should ask about symptoms, sleep, movement, thought, work, care of others, and safety. A symptom surge may call for a pause. The next change may need to be smaller or slower. A new health review may also be needed. This is not proof of weak effort.1

The guideline describes a common initial pace of roughly 5% to 10% every 2 to 4 weeks and says reductions should usually not exceed 25% every 2 weeks. This is consensus guidance, not a personal dose calendar or a proven optimal schedule. It cannot be used safely without individual assessment, monitoring, and adjustment by a qualified clinician.1

Here is one limited analogy. Think of the taper as an adjustable staircase with railings. Dose cuts are steps, not a cliff. A step may shrink, pause, or change pace. Therapy, sleep care, medical care, and family help are the railings. No fixed set of steps fits all people. The picture is not a dosing plan.

The last part may feel different from the first. Even a small cut can matter. Proportional, hyperbolic, and very small cuts have a sound theory or expert support. Yet no strong head-to-head trial shows that one named method is best. A drug form or pharmacy may allow smaller changes. That does not make self-made doses safe.1335

Some tapers take many months or longer. A lower steady dose or a partial cut may be a sound goal for now. Full stopping may not be safe or fit the person’s needs. Success can mean fewer falls, safer drug use, better daily life, or a stable lower dose. Care should continue after the last dose or a partial goal. Sleep, the first illness, use-disorder risk, and long symptoms may still need care.13

Should the person change to a longer-acting benzodiazepine?

A move to a longer-acting drug may smooth sharp rises and falls for some people. A clinician must manage it. Staying on the current drug is also sound. Current guidance makes the change an option, not a rule. Evidence that it improves lasting recovery is weak.13

The choice is not simple. Dose matches differ across trusted sources. Cross-tolerance may be incomplete, so a match on paper may not act like one. Long-lived drugs and active breakdown products can build up. This can cause long sedation. Older age, liver disease, other drugs, and drug interactions raise that risk. Kidney health can affect some drugs too.13

A short-acting drug is not always worse. A long-acting drug is not always safer. The plan must weigh the exact drug, its purpose, organ health, falls, driving, other sedatives, and past response. This article gives no dose match because those estimates need clinical judgment.1

When medical withdrawal management is needed

Medical withdrawal care is short-term care for urgent safety. Staff may check pulse, blood pressure, breathing, and symptoms often. They assess seizure risk. They treat fluid loss or other illness. They can move the person to emergency care fast if needed. This is not the same as residential addiction care. It also does not replace long-term care for anxiety or sleep.1

Phenobarbital may have a narrow role. It is for selected people in inpatient or medically managed care with adequate monitoring and clinicians experienced with the protocol. Evidence comes mainly from two hospital groups of 310 and 355 people, with no control group. Few seizures were recorded. In the group of 310, about one in four people had a dose held because of sedation. In the group of 355, a small number left before treatment was complete. Neither study showed that the drug beat a gradual taper or led to lasting recovery. It is not a home taper, a usual swap, or a drug to prevent return to use.11617

Flumazenil can reverse some sedation or overdose effects in medical care. That is its FDA role. It is not approved as a taper drug. In a person with dependence, it can cause sudden withdrawal, seizures, and heart-rhythm trouble. The 2025 guideline says not to use it for routine tapering. Propofol, ketamine, and rapid withdrawal under anesthesia are not standard taper care either.115

Emergency 1: possible severe withdrawal after stopping or reducing

Slow breathing is not the usual mechanism of withdrawal. It points toward overdose, mixed exposure, or another emergency and belongs on a separate pathway.12

Emergency 2: possible overdose or mixed exposure

Naloxone treats an opioid component, not benzodiazepine toxicity. Even if the person wakes, emergency care is still needed.1920

A separate self-harm crisis pathway

Suicidal intent, an attempt, or immediate danger is a third emergency pathway. Call 911 for immediate physical danger. Call or text 988 for U.S. suicide, mental-health, or substance-use crisis support when emergency medical rescue is not already required. Do not assume the danger is only withdrawal or addiction.24

Medication options: an evidence map, not a shopping list

A live Drugs@FDA and current-label review on August 31, 2026 found no medication approved for benzodiazepine withdrawal, benzodiazepine use disorder, or relapse prevention.1534 The 2018 Cochrane review included 38 trials with 2,543 people, but data could be extracted from 35 trials with 2,295 people. Nearly all medicine findings were low or very low certainty. Trials were often small and short. They also did a poor job of reporting harms. Current guidance does not name one add-on drug that works well for routine use.14

When taper symptoms interfere, slowing or pausing usually comes first.1 A drug may still help a clear symptom or the first illness. That is a different claim. Symptom relief does not prove safer withdrawal. It also does not prove taper success or recovery months later.

The medication evidence map

This map is for questions, not self-selection. Every proposed medicine needs a clear target, evidence review, interaction check, and plan for stopping it when appropriate.

Options that treat the original problem

The problem that led to drug use may still be there. Leaving it untreated can add distress and make the plan harder. Care should fit the diagnosis and the person’s goals. It should also fit past response and current risk. Not every anxious person needs an antidepressant. Not every sleepless person needs another sedative.

For generalized anxiety disorder, panic disorder, and social anxiety, matched CBT can help test feared ideas. It can also reduce avoidance. Exposure work is often key for panic and phobic fear. Selected SSRIs or SNRIs can help some people. Benefit usually builds over weeks. The choice must account for early activation and bipolar disorder. Pregnancy, age, bleeding, low sodium, interactions, and suicide risk also matter.31

For PTSD, trauma-focused therapy is first-line care. The VA/DoD guideline supports sertraline, paroxetine, or venlafaxine when a drug is chosen. It strongly recommends against benzodiazepines as PTSD treatment, while rating the direct evidence for that recommendation as very low. That is not an order to stop at once. A person with physical dependence still needs a safe taper review. PTSD and a substance use disorder should be treated together when possible.13

For long-term insomnia, CBT-I is first-line care. Some drugs are approved for insomnia. A drug does not become withdrawal or addiction care because it helps sleep. Z-drugs can still cause harm, falls, dependence, and withdrawal. Sleep apnea, restless legs, pain, body-clock timing, mania, and substance use may need care first.1112

Acute grief and situational distress often call for practical help, social support, sleep and safety support, and follow-up. Normal grief is not a disease that a sedative cures. Prolonged grief or a separate depressive, anxiety, trauma, or sleep disorder may need its own assessment.

Bipolar or psychotic illness needs added care. Major sleep loss can warn of a crisis or make one worse. If a taper threatens mania or psychosis, current guidance supports a pause. The illness also needs care. Casual antidepressant advice is unsafe here.132

Some uses sit outside a broad message about dose cuts. Epilepsy rescue plans can be urgent. So can care for status epilepticus. Catatonia may respond to a benzodiazepine or ECT under expert care. Benzodiazepines are first-line drugs for moderate or severe alcohol withdrawal in proper medical care. Palliative and end-of-life care follows comfort goals. These uses need expert review before any plan to cut the drug. A cut may not be the goal.1262728

Muscle spasm, spasticity, and pain-related use also need a cause-specific review. Physical therapy, activity, pain treatment, and other medicines may help in selected conditions. Yet a non-benzodiazepine option can bring its own sedation, falls, breathing, misuse, or interaction risk.

Pregnancy, postpartum, and nursing need a joint review. The team must weigh the parent’s illness and withdrawal risk. It must also weigh fetal or infant exposure, sleep loss, and untreated illness. A sudden stop is not safer by default. Obstetric, mental health, child, and pharmacy input may be needed.129

Withdrawal treatment is not the same as anxiety treatment

Psychotherapies: direct evidence and transferred evidence

Therapy evidence is strongest when it treats the first anxiety or sleep problem during a gradual taper. It is weaker when broad support is said to treat withdrawal itself. Therapy cannot stop a withdrawal seizure. It cannot replace medical checks for a high-risk person.

In a 2015 Cochrane review, CBT plus taper did better than taper or usual care in the short term. Just after care, 9 trials with 423 people gave a relative risk of 1.40. Its 95% confidence interval was 1.05 to 1.86. At 3 months, 9 trials with 575 people gave a relative risk of 1.51. That interval was 1.15 to 1.98. The review rated the short-term result as moderate certainty. Later results were not clear. The groups and therapy plans differed. They mixed long-term prescribed users with some opioid-dependent participants. Harms, function, and quality of life were reported poorly.5

A 2021 review focused on anxiety disorders. It had only 3 trials and 113 people. CBT plus taper did better than taper alone at 3 months. The relative risk was 1.96. At 6 to 12 months, it was 2.16. The result looks hopeful, but the evidence base is small. It does not show the same benefit for severe withdrawal or fake pills. It also may not apply to very high use, many drugs, or every anxiety disorder.6

Brief teaching can help some prescribed users start change. A 2020 review had 8 primary-care or pharmacy trials with 2,071 people. At 6 months, 8 studies gave a relative risk of 2.73, with a 95% confidence interval from 1.84 to 4.06. At 12 months, only 2 studies gave a relative risk of 3.41, from 2.22 to 5.25. The programs differed. Safety, symptoms, and function were measured in few studies. A 2025 BMJ review had 49 trials and more than 39,000 people. It found only low-certainty signs of help from patient teaching, drug review, or pharmacy support. Most studies involved mixed sleep drugs or insomnia. They did not focus on severe dependence or a diagnosed use disorder.89

CBT-I also has direct evidence when paired with gradual hypnotic reduction. Its tasks, short-term effect, and long-term limits are explained in the next section.

Motivational interviewing may help with mixed feelings. Yet direct evidence was only 4 studies with 80 people and very low certainty. One mindfulness trial had 70 people. Direct evidence is also thin or absent for contingency management, relapse work, family or couples care, peers, coaching, exercise, and most digital tools. These services may still help a person take part, cope, or treat another use disorder. They are not established ways to stop benzodiazepines.59

One 2026 U.S. trial tested the EMPOWER-ED digital program in 161 Veterans in primary care. At the 6-month visit, VA pharmacy records showed no benzodiazepine renewal during the prior 3 months for 10 of 82 people, 12.2%, versus 2 of 79, about 2.5 in 100, with usual care. This did not rule out prescriptions outside the VA or non-prescribed use. The adjusted odds ratio was 5.31, but its 95% confidence interval was wide, from 1.12 to 25.12. A cut of at least one-quarter, including no renewal, was sustained during that same 3-month window in 14 of 82 versus 6 of 79. That result was inconclusive, with an odds ratio of 2.51 and a confidence interval from 0.91 to 6.90. Anxiety, sleep, and general health did not clearly differ. Absolute no-renewal counts were small. Most participants were men with internet access, and several high-risk groups were excluded. The program included a self-taper schedule, but this selected trial does not establish safety for unsupervised or high-risk tapering.41

Individual, group, family, and integrated addiction care may be valuable when a use disorder or another condition is present. The evidence comes partly from broader substance-use care, not benzodiazepine-specific trials. That difference should shape the claim, not erase the service.

Why sleep hygiene alone is usually not enough

Sleep hygiene covers useful basics such as light, caffeine, noise, and a steady wake time. It is not the same as CBT-I. CBT-I is a structured treatment that changes the patterns that keep insomnia going. The American Academy of Sleep Medicine and VA/DoD recommend CBT-I for chronic insomnia and advise against using sleep-hygiene education alone as the full treatment.1112

Stimulus control works on the link between bed and wakefulness. It changes what a person does when sleep does not come. Sleep restriction or compression uses a sleep diary to bring time in bed closer to actual sleep, then adjusts it. Cognitive work addresses fear of wakefulness, clock watching, rigid rules, and the effort to force sleep. A full plan also checks body-clock timing, light, shift work, and relapse risk.

These tasks can cause short-term tiredness or discomfort. The plan needs extra care for driving, hazardous work, falls, frailty, seizures, pregnancy, and bipolar or psychotic illness. It also needs review for sleep apnea, restless legs, pain, breathing disease, medicines, alcohol, cannabis, and other substances. No public article should assign a sleep window to an individual.

A 2019 meta-analysis included 8 trials and 482 adults with chronic insomnia. In the taper or usual-care groups, 64 of 238 people, or 26.9%, stopped the hypnotic in the short term. CBT-I plus taper had a pooled relative risk of 1.68, with a 95% confidence interval from 1.19 to 2.39. Applying that effect to the control rate gives an estimated 45.2%, not a raw pooled CBT-I rate. At 12 months, 4 trials with 256 people gave a relative risk of 1.67, from 0.91 to 3.07, so the lasting effect was inconclusive. Short-term insomnia improved, but daytime function did not clearly differ.7

A newer trial studied 188 adults age 55 or older taking low-dose benzodiazepine receptor agonists, including zolpidem, who met several safety limits. At the 6-month follow-up, 64 of 87 people, about 73%, reported no use in the prior 7 days after a masked taper plus enhanced CBT-I. The result was 52 of 89, about 58%, after an open taper plus standard CBT-I. The site-adjusted odds ratio was 1.95, with a 95% confidence interval from 1.03 to 3.70. This gives moderate confidence in one bundled outpatient program for selected older adults, not in CBT-I alone. The program used close follow-up and pharmacy support. It cannot be turned into a home method, and the findings do not transfer cleanly to high-risk withdrawal or a use disorder.10

What CBT and CBT-I actually ask you to do

When “rehab” helps and when it may not be necessary

Residential care can provide 24-hour structure for selected needs. It may fit a use disorder, major mental health need, unsafe home, or need for all-day support. No comparative study shows that residential rehabilitation improves benzodiazepine discontinuation or sustained recovery over intensive outpatient or partial-hospital care. Physical dependence alone does not prove a need for residential addiction care. Many people with prescribed dependence can receive safe outpatient care.1933

Program quality matters more than luxury, location, or a short stay. A program should name the medical staff who are present. It should explain how it checks seizure and delirium risk. It should say what happens when symptoms get worse. It must also define success. Counting only people who reached the last dose leaves out those who left early or returned to use.

Medical withdrawal care handles urgent risk. Rehab and follow-up care have other jobs. They address use patterns, the first illness, housing, work, and risk of return to use. A good program links these jobs. It does not call the end of withdrawal the end of care.

What a good treatment program should provide

Treating other substance use at the same time

Other substances can change both withdrawal and overdose risk. Alcohol may add sedation and breathing danger, and its own withdrawal can cause seizures or delirium. Opioids raise the risk of fatal breathing suppression. Z-drugs and gabapentinoids can add impairment, dependence, and withdrawal. Cannabis and stimulants can affect sleep, anxiety, mood, and judgment. Each substance needs its own honest assessment and treatment plan.1143739

Benzodiazepine use is not a reason to withhold or disrupt buprenorphine or methadone. Those medicines reduce harm from opioid use disorder. The team should treat the opioid use disorder at the same time, coordinate prescribers, review sedation, and provide naloxone. Requiring a person to finish a benzodiazepine taper before receiving opioid-use-disorder treatment can increase danger.118

Pills sold as alprazolam or another prescription drug may contain fentanyl, another unfamiliar benzodiazepine, or several substances. Their dose and duration cannot be read from appearance. Routine toxicology may miss some of them. Do not source replacement pills or build a taper from an illicit label. Seek prompt medical or addiction assessment.212240

Fentanyl test strips and drug-checking services may reduce uncertainty where they are legal and available. A negative result does not prove a pill is safe. A strip does not identify every opioid, the benzodiazepine, its strength, or all other contents. If a person cannot be awakened or has slow breathing, call 911 first and use naloxone if opioid exposure is possible.192021

Harm reduction also means not using alcohol, cannabis, kratom, a Z-drug, another person’s medicine, or an illicit sedative as a replacement. It can include safer storage, not using alone, naloxone access, overdose education, case management, and a plan for an interrupted supply. These steps reduce risk while treatment continues.

A difficult week does not mean treatment failed

Symptoms can come in waves. A hard week may be withdrawal or rebound. The first illness may have come back. Poor sleep, a new drug effect, or another illness may also play a part. Timing helps. The cause may stay unclear until the team watches it over time.

A pause or smaller next step gives the team useful facts. It is not defeat. Return to use is also useful information. The pace may have been too fast. The first illness may lack care. Access may have failed, or a trigger may have been missed. More help or a new setting may be needed. The answer is a new review and safety plan, not shame.

Some people report symptoms that continue in waves for months or longer after the last dose. These reports should not be dismissed. Research cannot yet give a dependable rate, cause, usual duration, forecast, or best treatment. Persistent symptoms also require review for sleep illness, the original disorder, medication effects, substance use, and other medical or psychiatric causes. They do not prove permanent brain injury.138

Recovery may include better function before every symptom is gone. It may also include a stable partial reduction rather than full discontinuation. Care for benzodiazepine use disorder, anxiety, insomnia, PTSD, housing, relationships, and overdose risk should continue as long as those needs remain.

Building the next 30 days

Thirty days is a planning window, not a taper calendar. The first aim is to build an accurate picture and connect it to the right care. Start a complete list of prescriptions, over-the-counter products, supplements, alcohol, cannabis, opioids, Z-drugs, gabapentinoids, stimulants, and non-prescribed pills. Add what is known about timing and source. Write “unknown” rather than guessing.

Record the reason the benzodiazepine was started and what benefit it gives now. Note missed-dose symptoms, sleep changes, falls, memory trouble, past reduction attempts, and any seizure, delirium, overdose, or self-harm event. Add practical barriers such as transport, cost, unsafe storage, or trouble reaching the prescriber.

Choose one support person, if wanted, and agree on the role before a crisis. The role may be taking notes, arranging rides, helping with meals, or keeping emergency instructions visible. It is not deciding the dose or controlling the medication.

Questions to take to the first appointment

Family job: be a co-pilot, not a corrections officer

Family guidance is based mainly on safety consensus and broader behavioral-health practice, not trials showing that family monitoring improves discontinuation. The patient’s consent and autonomy remain central.133

U.S. emergency and treatment resources

• 911 for life-threatening withdrawal, overdose, breathing trouble, inability to wake, seizure, collapse, an attempt, or immediate danger. Call before searching online. Be ready to give the emergency location and callback number, responsiveness, breathing, seizure, injury, suspected substances, naloxone use, and recent reduction or last dose if known.
• Poison Control: 1-800-222-1222 (Poison Help; Poison Control) for poisoning guidance when there are no current life-threatening signs. It is not a substitute for 911 when breathing is impaired, the person collapses, has a seizure, or cannot be awakened. Have the product or container if available, age and weight if known, amount and time if known, symptoms, health history, other substances, and aid already given. Do not guess the weight.
• 988 Suicide & Crisis Lifeline: call or text 988 (988lifeline.org) for suicide, mental-health, or substance-use crisis support. It is not medical withdrawal monitoring. Use 911 for immediate physical danger.
• Treatment information and referral: FindTreatment.gov and the SAMHSA National Helpline at 1-800-662-HELP (4357). FindTreatment.gov lists state-licensed facilities. A listing does not establish current benzodiazepine-withdrawal capability, quality, staffing, emergency capacity, or buprenorphine or methadone continuity. These services do not monitor withdrawal or provide emergency care.25

For a possible poisoning while the person is awake and breathing normally, Poison Control can guide the next step. Tell the specialist the product and amount if known, the time, symptoms, age, weight if known, health conditions, other medicines or substances, and any aid already given. Do not guess the weight or the identity or strength of a counterfeit pill.23

Before the next day ends, make the medicine and substance list and book an assessment with a clinician or service that can explain its benzodiazepine-withdrawal skills and emergency capacity.

Frequently asked questions

Is there a medicine that treats benzodiazepine withdrawal?

No. A live Drugs@FDA and current-label review on August 31, 2026 found no medication approved for benzodiazepine withdrawal, benzodiazepine use disorder, or relapse prevention. Some medicines can treat the original anxiety, sleep, or PTSD problem, but that is a different claim, and none of them is a withdrawal antidote.141534

How fast should a taper go?

There is no schedule that fits everyone. The 2025 Joint Clinical Practice Guideline describes a gradual, shared process with a check after every cut, and says a symptom surge may call for a pause or a smaller next step. Its pacing numbers are consensus guidance, not a personal dose calendar, and they cannot be used safely without a clinician.1

Do I have to switch to a longer-acting benzodiazepine first?

No. Current guidance makes the switch an option, not a rule. It may smooth sharp rises and falls for some people, but dose matches differ between sources, cross-tolerance can be incomplete, and long-lived drugs can build up. Staying on the current medicine is also sound.13

Do I need rehab?

Not because of dependence alone. No comparative study shows that residential rehabilitation improves benzodiazepine discontinuation or lasting recovery over outpatient care. Residential care can fit a use disorder, a major mental health need, or an unsafe home. Many people with prescribed dependence receive safe outpatient care.1933

I had a terrible week. Did the taper fail?

No. A hard week is information. It may be withdrawal, rebound, the first illness returning, poor sleep, or something else. A pause or a smaller next step gives the team useful facts, and return to use is a reason for a new review and safety plan, not shame.1

Can I stay on buprenorphine or methadone while I taper?

Yes. Benzodiazepine use is not a reason to withhold or disrupt buprenorphine or methadone. The team should treat the opioid use disorder at the same time, coordinate prescribers, review sedation, and provide naloxone.118

Related reading on NP FADY

• Benzodiazepines: When the Medicine Becomes Hard to Stop (Part 1)
• What Benzodiazepines Actually Do to the Brain’s Brakes
• CBT Made Simple: How Changing Thoughts Changes Feelings
• Sleep Anxiety: Tired of Being Tired? The Science of Sleeping Without Pills
• How PTSD Is Treated Today: What Works, and What Order to Try It In
• Buspirone (BuSpar) for Anxiety: How It Works, Side Effects, and How It Compares With Benzodiazepines and SSRIs
• Treating Kratom Dependence and Addiction: What Recovery Looks Like

References

1. Brunner E, Chen C-YA, Klein T, et al. Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Benzodiazepine Risks Outweigh Benefits. Journal of General Internal Medicine. 2025;40:2814-2859. DOI 10.1007/s11606-025-09499-2; official guideline PDF.

2. U.S. Food and Drug Administration. FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class. September 23, 2020. FDA Drug Safety Communication.

3. National Institute for Health and Care Excellence. Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults. NG215. Current guidance.

4. Baandrup L, Ebdrup BH, Rasmussen JØ, et al. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Database of Systematic Reviews. 2018;3:CD011481. DOI 10.1002/14651858.CD011481.pub2; PMID 29543325; full text.

5. Darker CD, Sweeney BP, Barry JM, Farrell MF, Donnelly-Swift E. Psychosocial interventions for benzodiazepine harmful use, abuse or dependence. Cochrane Database of Systematic Reviews. 2015;5:CD009652. DOI 10.1002/14651858.CD009652.pub2; PMID 26106751; full text.

6. Takeshima M, Otsubo T, Funada D, et al. Does cognitive behavioral therapy for anxiety disorders assist the discontinuation of benzodiazepines among patients with anxiety disorders? Psychiatry and Clinical Neurosciences. 2021;75:119-127. DOI 10.1111/pcn.13195; PMID 33448517.

7. Takaesu Y, Utsumi T, Okajima I, et al. Psychosocial intervention for discontinuing benzodiazepine hypnotics in patients with chronic insomnia: a systematic review and meta-analysis. Sleep Medicine Reviews. 2019;48:101214. DOI 10.1016/j.smrv.2019.101214; PMID 31648145.

8. Lynch T, Ryan C, Hughes CM, et al. Brief interventions targeting long-term benzodiazepine and Z-drug use in primary care: a systematic review and meta-analysis. Addiction. 2020;115:1618-1639. DOI 10.1111/add.14981; PMID 31985127.

9. Zeraatkar D, et al. Comparative effectiveness of interventions to facilitate deprescribing of benzodiazepines and other sedative-hypnotics in adults: systematic review and meta-analysis. BMJ. 2025;389:e081336. DOI 10.1136/bmj-2024-081336; PMID 40527546.

10. Fung CH, Alessi C, Martin JL, et al. Masked Taper With Behavioral Intervention for Discontinuation of Benzodiazepine Receptor Agonists: A Randomized Clinical Trial. JAMA Internal Medicine. 2024;184:1448-1456. DOI 10.1001/jamainternmed.2024.5020; PMID 39374004.

11. Edinger JD, Arnedt JT, Bertisch SM, et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine. 2021;17:255-262. Full text.

12. U.S. Department of Veterans Affairs and Department of Defense. Clinical Practice Guideline for the Management of Chronic Insomnia Disorder and Obstructive Sleep Apnea. 2025. Official guideline.

13. U.S. Department of Veterans Affairs and Department of Defense. Clinical Practice Guideline for Management of Posttraumatic Stress Disorder and Acute Stress Disorder. 2023. Official guideline.

14. U.S. Food and Drug Administration. Serious breathing problems with gabapentin and pregabalin in people with respiratory risk factors or other central nervous system depressants. 2019. FDA safety communication.

15. DailyMed. Flumazenil injection, current U.S. labeling. Current label.

16. Kawasaki SS, Jacapraro JS, Rastegar DA. Safety and effectiveness of a fixed-dose phenobarbital protocol for inpatient benzodiazepine detoxification. Journal of Substance Abuse Treatment. 2012;43:331-334. DOI 10.1016/j.jsat.2011.12.011; PMID 22285834.

17. Sartori S, Crescioli G, Brilli V, et al. Phenobarbital use in benzodiazepine and Z-drug detoxification: a single-centre 15-year observational retrospective study. Internal and Emergency Medicine. 2022;17:1631-1640. DOI 10.1007/s11739-022-02976-0; full text.

18. U.S. Food and Drug Administration. 2017 action on careful management rather than withholding opioid-use-disorder medicines from patients taking benzodiazepines or other CNS depressants. FDA overdose-prevention timeline. Checked August 31, 2026.

19. Centers for Disease Control and Prevention. What to Do If You Think Someone Is Overdosing. Official overdose response. Checked August 31, 2026.

20. Centers for Disease Control and Prevention. Five Things to Know About Naloxone. Official naloxone guidance. Checked August 31, 2026.

21. Centers for Disease Control and Prevention. Fentanyl and fentanyl test strips. Official fentanyl guidance. Checked August 31, 2026.

22. Lund K, Menlyadiev M, Lee K. Comparison of two highly sensitive benzodiazepine immunoassay lab developed tests for urine drug testing in clinical specimens. Journal of Mass Spectrometry and Advances in the Clinical Lab. 2023;28:91-98. DOI 10.1016/j.jmsacl.2023.02.010; full text.

23. Poison Control and Health Resources and Services Administration. Poison Control help; Poison Help guidance. Checked August 31, 2026.

24. 988 Suicide & Crisis Lifeline. Official 988 site. Checked August 31, 2026.

25. Substance Abuse and Mental Health Services Administration. FindTreatment.gov; National Helpline. Checked August 31, 2026.

26. American Society of Addiction Medicine. Clinical Practice Guideline on Alcohol Withdrawal Management. 2020. Official guideline.

27. Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults. Epilepsy Currents. 2016;16:48-61. Full text.

28. Rogers JP, Oldham MA, Fricchione G, et al. Evidence-based consensus guidelines for the management of catatonia. Journal of Psychopharmacology. 2023;37:327-369. DOI 10.1177/02698811231158232; full text.

29. American College of Obstetricians and Gynecologists. Treatment and Management of Mental Health Conditions During Pregnancy and Postpartum. Clinical Practice Guideline No. 5. 2023. Official guideline page.

30. 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2023;71:2052-2081. DOI 10.1111/jgs.18372.

31. National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder in adults, CG113; Social anxiety disorder, CG159.

32. U.S. Department of Veterans Affairs and Department of Defense. Clinical Practice Guideline for the Management of Bipolar Disorder in Adults. 2023. Official guideline.

33. Substance Abuse and Mental Health Services Administration. Types of treatment; treatment for co-occurring disorders.

34. DailyMed, Drugs@FDA, FDA, and eCFR. Current U.S. regulatory sources reviewed for phenobarbital, carbamazepine, divalproex, pregabalin, gabapentin, buspirone, paroxetine, mirtazapine, trazodone, low-dose doxepin, ramelteon, daridorexant, lemborexant, suvorexant, hydroxyzine, propranolol, clonidine, zolpidem, eszopiclone, zaleplon, propofol, and ketamine; the FDA explanation of off-label use; the Drugs@FDA database; Schedule IV and Schedule V. Checked August 31, 2026.

35. Kleykamp BA, et al. Benzodiazepine Tapering: Evidence Limitations and Research Recommendations. Journal of Addiction Medicine. 2026. DOI 10.1097/ADM.0000000000001715; PMID 42160770.

36. U.S. Food and Drug Administration. Certain Prescription Insomnia Medicines: New Boxed Warning Due to Risk of Serious Injuries Caused by Sleepwalking, Sleep Driving and Engaging in Other Activities While Not Fully Awake. 2019. Current FDA MedWatch page. Checked August 31, 2026.

37. National Institute on Alcohol Abuse and Alcoholism. Alcohol-Medication Interactions: Potentially Dangerous Mixes. Updated 2025. Official resource.

38. Shade KN, Ritvo AD, Huff C, et al. Long-term neurological consequences following benzodiazepine exposure: a scoping review. PLOS One. 2025;20:e0330277. DOI 10.1371/journal.pone.0330277.

39. National Institute on Drug Abuse. Benzodiazepines and Opioids. Official resource. Checked August 31, 2026.

40. O’Donnell J, Tanz LJ, Miller KD, et al. Drug overdose deaths with evidence of counterfeit pill use, United States, July 2019 to December 2021. MMWR. 2023;72:949-956. CDC report.

41. Humphreys K, Hagedorn H, Han X, et al. Electronic Intervention for Patient-Managed Benzodiazepine Tapering: A Randomized Clinical Trial. JAMA Network Open. 2026;9(1):e2551807. DOI 10.1001/jamanetworkopen.2025.51807; PMID 41533380; full text.

42. Toce MS, Michelson KA, Hudgins JD, et al. Trends in benzodiazepine prescribing for U.S. adolescents and young adults from 2008 to 2019. JAMA Pediatrics. 2022;176:312-313. DOI 10.1001/jamapediatrics.2021.5122; PMID 34928314.

---

This article provides general education, not personal medical advice, diagnosis, or a taper plan. Reading it does not create a clinician-patient relationship. Do not start, stop, switch, or change a benzodiazepine dose without a qualified clinician. The guideline pacing figures quoted above are consensus guidance for clinicians and cannot be used as a personal schedule. Emergency symptoms require emergency care. Evidence and U.S. guidance were checked on August 31, 2026.

If you or someone you know is in crisis

• Call 911 or go to your nearest emergency room for any life-threatening emergency.
• 988 Suicide & Crisis Lifeline — call or text 988, available 24/7. En español: marque 988 y oprima 2. Veterans: 988 and press 1, or text 838255.
• Crisis Text Line — text HOME to 741741.
• The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
• National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
• National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
• Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
• San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
• Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
• California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
• NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.